-23%

Vitaresp FX 180mg Tablet 10’S

$10.00

Vitaresp FX 180mg Tablet 10’S

Vitaresp FX 180mg Tablet 10’S

$10.00

Add to cart
Buy Now
SKU: EX-102190 Category: Tag:
Description

Product Description

Description

Vitaresp FX 180 Tablet is a combination medicine that consists of Montelukast and Fexofenadine. It is used to treat year-round symptoms of allergic rhinitis such as runny nose, watery eyes, sneezing, itching, etc. Vitaresp FX 180 Tablet stops the activity of the chemical substance that causes allergic symptoms. Vitaresp FX 180 Tablet shows some common side effects like drowsiness, rash, weakness, headache, etc. Consult your doctor if any of these symptoms persist for a long time. Avoid using this medicine if you are allergic to it. Vitaresp FX 180 Tablet is not recommended for use in children below 12 years of age. Avoid driving vehicles or operating machines after taking this medicine as it can cause dizziness. Avoid consuming alcohol while taking this medicine as it can worsen drowsiness. Vitaresp FX 180 Tablet can be taken with or without food. Your doctor will decide the dose and duration of treatment based on your condition. Finish your entire course of treatment with Vitaresp FX 180 Tablet, even if the condition gets better after taking a few doses. Consult your doctor if you still feel unwell after completing your treatment course. Vitaresp FX 180 Tablet may not be suitable for all people. Consult your doctor before taking this medicine if you are pregnant or are breastfeeding. Inform your doctor if you have kidney or liver problems and also about the medicines that you may be using. Do not share your medicine with other people even if the symptoms appear to be similar. Stop taking it at least three days before undergoing any allergy test to ensure accuracy of test results.

 

Category from : Vitaresp FX 180mg Tablet 10’S

Brand

Brand

Alembic Pharmaceuticals Ltd

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Vitaresp FX 180mg Tablet 10’S”

Your email address will not be published.

Top